Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 03, 2015 8:50 PM ET

Company Overview of Weill Cornell Medical College, New York

Company Overview

Weill Cornell Medical College, New York is an educational institution.

525 East 68th Street

New York, NY 10065

United States

Phone:

212-746-1050

Fax:

212-746-8341

Key Executives for Weill Cornell Medical College, New York

Weill Cornell Medical College, New York does not have any Key Executives recorded.

Weill Cornell Medical College, New York Key Developments

Weill Cornell Medical College and Cellectis Announces Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia

Weill Cornell Medical College and Cellectis have entered into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML), a deadly blood cancer. The alliance will foster the development of Cellectis lead product candidate in AML, called UCART123. The collaboration combines Weill Cornell's broad expertise and resources in translational stem cell science and developmental therapeutics with Cellectis work in development and manufacturing of gene edited CAR-T cell product candidates, a special kind of immune cell that includes an antibody-derived receptor. The research will be led by co-principal investigators Dr. Gail J. Roboz, director of the leukemia program and an associate professor of medicine at Weill Cornell, and Dr. Monica Guzman, an assistant professor of pharmacology in medicine at Weill Cornell. Dr. Roboz is an internationally recognized leader in the field of acute leukemia and will design and implement clinical testing of UCART123 in patients with AML. Dr. Guzman is a renowned leukemia stem cell biologist who specializes in preclinical and early-stage testing to optimize the development of stem cell-targeted cancer drugs. The alliance will seek to accelerate the development of Cellectis UCART123 in AML. Cellectis proprietary allogeneic CAR T-cell platform utilizes T-cells (immune cells) from healthy donors. The T-cells are engineered with a Chimeric Antigen Receptor (CAR), which enables them to detect specific proteins (antigens) expressed on malignant tumors. Large numbers of allogeneic CAR-modified T-cells are grown in the laboratory and then infused into a patient. The enhanced cells are designed to recognize and attack stem cells harboring the CD123 antigen, which is present on AML blast and stem cells. To enhance safety and minimize toxicity for patients, the company's gene-editing process features customized control properties that seek to prevent the T cells from inappropriately attacking healthy tissues.

Dr. Silvia C. Formenti Joins as Chair of the Newly Established Department of Radiation Oncology at Weill Cornell Medical College, Effective April 15

Dr.  Silvia C.  Formenti has been appointed chair of the  newly established Department of Radiation Oncology at Weill Cornell Medical College, effective April 15. Dr.   Formenti, currently the chair  of radiation oncology at  New York University  Langone Medical  Center, has also been named the associate director of radiation oncology at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College.

Weill Cornell Medical College Announces Change of Chairman, Effective Jan. 1, 2015

After 20 years of bold and visionary leadership that has transformed Weill Cornell Medical College into a global healthcare enterprise, Sanford I. Weill will retire as chair of the Weill Cornell Board of Overseers on Jan. 1, 2015. Jessica M. Bibliowicz, a successful entrepreneur in the financial services business for nearly three decades, who has served on the Board of Overseers for the past decade, will succeed Mr. Weill, the new chair emeritus. In collaboration with medical college leadership, Ms. Bibliowicz will help lead Weill Cornell as it continues to break new ground in New York and abroad by expanding its clinical enterprise and forging public-private partnerships that accelerate groundbreaking scientific discoveries for patients. Working closely with Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, Ms. Bibliowicz will help guide its transformation of medical education and drive dialogue on innovative healthcare delivery models that optimize the value and quality of patient care. Currently, Ms. Bibliowicz is a senior advisor at Bridge Growth Partners and serves on the board of directors of Sotheby's; Realogy; and the Asia Pacific Fund. She is a board director/trustee of Prudential Insurance Funds and is also on the board of Jazz at Lincoln Center.

Similar Private Companies By Industry

Company Name Region
The Binding Site Inc United States
Reliant Energy HL&P United States
Premark Packaging LLC United States
SDV, LLC United States
The Charter Group, Ltd. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Weill Cornell Medical College, New York, please visit www.med.cornell.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.